“Sturge-Weber syndrome results in leptomeningeal vascular malformations, medically refractory epilepsy, stroke(s), and cognitive impairments. Cannabidiol, a cannabinoid without psychoactive properties, has been demonstrated in preclinical models to possibly have anticonvulsant, antioxidant, and neuroprotective actions.
Monthly Archives: April 2017
Cannabis use by women during pregnancy does not influence infant DNA methylation of the dopamine receptor DRD4.
“Associations between cannabis use and offspring DNA methylation have not been investigated; however, maternal tobacco smoking in pregnancy is associated with distinct patterns of DNA methylation at birth and beyond. To determine whether maternal cannabis use is associated with methylation of the dopamine receptor gene DRD4 promoter in infants. There is no strong evidence that maternal cannabis use in pregnancy is associated with offspring DRD4 methylation.” https://www.ncbi.nlm.nih.gov/pubmed/28448718
“There is no strong evidence that maternal cannabis use in pregnancy is associated with offspring DRD4 methylation.” http://www.tandfonline.com/doi/abs/10.1080/00952990.2017.1314488?journalCode=iada20
]]>
Marijuana compounds show promise in treatment of cardiac disease
“A Nevada company is hoping to develop new medicines for heart failure using compounds in marijuana and a novel therapy identified by a University of Hawaiʻi at Mānoa researcher. Dr. Alexander Stokes, assistant research professor in the Department of Cell and Molecular Biology at the UH John A. Burns School of Medicine, obtained a U.S. patent for his novel therapy in 2015. The patent claims the cannabinoid receptor TRPV1 can be regulated therapeutically by plant-based cannabinoids.” https://medicalxpress.com/news/2017-01-marijuana-compounds-treatment-cardiac-disease.html
“Marijuana compounds show promise in treatment of cardiac disease” http://manoa.hawaii.edu/news/article.php?aId=8355
“Marijuana compounds show promise in treatment of cardiac disease” http://www.hawaii.edu/news/2017/01/12/marijuana-compounds-show-promise-in-treatment-of-cardiac-disease/
]]>Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols.
“Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS).
We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols.
Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS.
Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting.”
